A tuberculoma is a granuloma of central nervous system tuberculosis, and on MRI it is recognised not by ring enhancement, which almost every intracranial mass produces, but by what sits inside the ring: a T2 hypointense caseous core, a large lipid resonance on spectroscopy and a choline peak that stays low. Those three features are what separate it from a high-grade glioma, a metastasis, a pyogenic abscess and neurocysticercosis, which are the four differentials that matter in practice.
This article is a working reference for reading a suspected tuberculoma: the pathology behind each MRI appearance, the four conventional patterns and how the T2 signal shifts between them, what diffusion, spectroscopy, susceptibility, magnetization transfer and perfusion actually add with the published numbers, then side-by-side comparisons against glioma, neurocysticercosis and abscess, a reporting checklist, and what happens to the lesion on treatment. Clinical anchors are the 2026 international tuberculous meningitis clinical practice guideline [12], WHO consolidated guidelines module 4 [13] and NICE NG33 [14].
- Key facts for practice and radiology exams
- What is a tuberculoma?
- Tuberculoma on MRI: the four appearances
- Advanced MRI in tuberculoma: what each sequence actually adds
- Tuberculoma vs glioma on MRI
- Tuberculoma vs neurocysticercosis
- Tuberculoma vs abscess and the wider ring-enhancing differential
- Other patterns of CNS tuberculosis to look for
- How to report a suspected tuberculoma
- Treatment, follow-up imaging and the paradoxical response
- Frequently asked questions
- References
Key facts for practice and radiology exams
- The T2 hypointense core is the single most useful conventional sign. Solid caseous necrosis is dehydrated, protein-rich and contains paramagnetic free radicals, so it shortens T2. Measured T2 relaxation time is about 161 ms for tuberculomas against about 617 ms for cysticercal cysts [8].
- Diffusion tracks liquefaction, not aetiology. A solid caseating tuberculoma does not restrict (core ADC about 1.24). Once the centre liquefies it does (about 0.74 to 0.80), and a tuberculous abscess restricts markedly (about 0.61) [1].
- Spectroscopy is the discriminator against tumour. Large lipid and lactate at 0.9 to 1.3 ppm with a Cho/Cr of about 1.36, against about 2.63 for malignant lesions [4]. Lipid was seen in 86 percent of tuberculomas but only 20 percent of neurocysticercosis lesions [7].
- A complete, regular hypointense peripheral ring on SWI was present in 58 percent of tuberculomas and in none of the malignant lesions in a 116-patient prospective series [4].
- Perfusion separates tuberculoma from neurocysticercosis, not from glioma. The granulation-tissue wall of a tuberculoma is hypervascular: mean wall rCBV about 3.3 against about 1.3 for neurocysticercosis, cut-off near 2.0 giving 90 percent sensitivity and 100 percent specificity [5]. Against grade 4 glioma it is the glioma that has the higher rCBV [3].
- Multiplicity, basal exudates, hydrocephalus and basal ganglia infarcts alongside the lesion move the diagnosis decisively towards tuberculosis. Hydrocephalus occurs in 50 to 90 percent and infarction in more than 65 percent of tuberculous meningitis [12].
- Getting bigger on treatment is expected, not failure. Inflammatory intracerebral complications occur in around 20 percent of patients with tuberculous meningitis and in more than 30 percent of those living with HIV [12].
- Treatment is 12 months, not 6. NICE NG33: 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol then 10 months of isoniazid and rifampicin, with adjunctive corticosteroids tapered over 4 to 8 weeks [14].
What is a tuberculoma?
A tuberculoma is a mature granuloma formed when haematogenously seeded Mycobacterium tuberculosis is walled off in the brain parenchyma. The seed is a Rich focus, a small subpial or subependymal tubercle deposited during the bacillaemia of primary infection. If it enlarges into the parenchyma it becomes a tuberculoma; if it ruptures into the subarachnoid space it produces tuberculous meningitis. That shared origin is why the two so often coexist and why finding one obliges you to look for the other.
Tuberculosis remains the world leading infectious killer, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024 [15]. Intracranial tuberculoma is therefore a routine differential wherever tuberculosis is endemic, and an easily missed one where it is not. Roughly half of patients with tuberculous meningitis have concurrent pulmonary tuberculosis, so a chest radiograph and sputum testing are part of the imaging workup rather than an afterthought [12].
Histology dictates signal. The centre of the granuloma passes through three states, and each has its own MRI appearance:
- Non-caseating granuloma: epithelioid cells, Langhans giant cells and lymphocytes, no central necrosis, relatively high free water.
- Caseating granuloma with a solid centre: dry, dehydrated, lipid- and protein-rich caseous necrosis containing macrophage-derived free radicals.
- Caseating granuloma with central liquefaction: the caseum breaks down and free water returns, the step before a frank tuberculous abscess.
Tuberculoma on MRI: the four appearances
Almost every confusing tuberculoma is confusing because the reader expects one fixed appearance. There are four, they sit on a continuum, and a single patient can show more than one simultaneously. The apparent diffusion coefficient values below are from a series of 70 tuberculomas and tuberculous abscesses grouped by their T2 core signal [1], all in units of 10-3 mm2/s.
| Stage | T1 | T2 | Enhancement | Core ADC | Wall ADC |
|---|---|---|---|---|---|
| Non-caseating granuloma | Hypo to isointense | Hyperintense | Homogeneous, nodular, solid | Not applicable (no necrotic core) | Not applicable |
| Caseating, solid centre | Iso to hypointense with a hyperintense rim | Hypointense core, hyperintense rim | Smooth thin complete rim | 1.24 (SD 0.32), higher than the wall | 1.06 (SD 0.15) |
| Caseating, central liquefaction | Hypointense centre | Mildly hyperintense core | Rim, sometimes slightly irregular | 0.80 (SD 0.08), lower than the wall | 1.08 (SD 0.13) |
| Frankly hyperintense tuberculoma | Hypointense | Markedly hyperintense | Rim | 0.74 (SD 0.13) | 1.03 (SD 0.14) |
| Tuberculous abscess | Hypointense | Markedly hyperintense | Thin smooth rim, usually larger and often solitary | 0.61 (SD 0.08) | 1.08 (SD 0.14) |
Two practical consequences follow. First, a lesion that does not restrict has not excluded tuberculoma, it has told you the caseum is still solid. Second, there was no significant difference in ADC between a tuberculous abscess and a frankly T2 hyperintense tuberculoma [1], so diffusion cannot be used to declare a lesion an abscess rather than a liquefying granuloma.
Distribution, size and mass effect
- Location. Corticomedullary junction and periventricular white matter most often, following the arterial border zones of haematogenous seeding, with the basal ganglia and thalami also typical. Supratentorial lesions predominate in adults; infratentorial and cerebellar lesions are classically described as relatively more common in children.
- Number. Frequently multiple, and multiplicity in a patient from an endemic area with systemic symptoms is a strong pointer.
- Size. Most are 10 to 25 mm. A tuberculoma larger than 2 cm is called a giant tuberculoma and is the one most often mistaken for a glioma [3].
- Mass effect. Characteristically modest for the amount of surrounding vasogenic oedema. A large tumour-like mass effect argues against tuberculoma.
- Calcification. Seen in healed and long-standing lesions. Central calcification with peripheral enhancement produces the target sign, which is suggestive of tuberculoma but is not pathognomonic and is also described in other granulomas.
Advanced MRI in tuberculoma: what each sequence actually adds
This is where the diagnosis is usually made or unmade, and where the published evidence is more nuanced than the textbook summaries suggest.
| Technique | Finding in tuberculoma | Discriminatory value |
|---|---|---|
| MR spectroscopy | Dominant lipid and lactate at 0.9 to 1.3 ppm; choline normal or mildly raised; NAA and creatine low or absent. Cho/Cr about 1.36 (SD 0.41). | Strong against tumour: malignant lesions had Cho/Cr about 2.63 (SD 0.99) [4]. Lipid present in 86 percent of tuberculomas against 20 percent of neurocysticercosis [7]. Lipid alone is not specific, since necrotic gliomas and metastases also produce it. |
| Diffusion-weighted imaging | Core ADC varies with stage, from 1.24 (solid caseation) down to 0.61 (abscess) [1]. | Good against neurocysticercosis, where the core ADC is 1.51 to 1.66 [1]. Contested against tumour: one series found minimum ADC the best single discriminator from high-grade glioma at 93.8 percent accuracy [2], another found no significant difference from gliomas or metastases [4]. |
| Susceptibility-weighted imaging | A complete, regular hypointense peripheral ring. | Present in 58 percent of tuberculomas and in none of the malignant lesions in a 116-patient prospective study [4]. When present it is one of the more useful positive findings. |
| Magnetization transfer imaging | A characteristic T1 hyperintense rim on MT images; higher MT ratio in the non-enhancing core than in tumour necrosis. | Core MTR 0.14 (SD 0.29) against minus 0.19 (SD 0.22) for necrotic high-grade glioma; sensitivity 68 percent, specificity 80 percent, accuracy 77 percent as a standalone test [9]. A T1 hyperintense MT rim was present in 78 percent of giant tuberculomas [3]. |
| DSC perfusion | Hypervascular granulation-tissue wall, hypovascular core; overshoot of the signal intensity-time curve above baseline in 9 of 10 giant tuberculomas [3]. | Excellent against neurocysticercosis: wall rCBV about 3.3 against 1.3, cut-off 1.965 giving 90 percent sensitivity and 100 percent specificity [5]. Against grade 4 glioma the direction reverses, with glioma showing the higher rCBV [3]. |
| T2 relaxometry | Mean T2 relaxation time 161 ms, range 83 to 290 ms. | Cysticercal cysts measured 617 ms, range 305 to 1365 ms, with no overlap in that series [8]. |
| Synthetic MRI and DCE | Higher pre-contrast core R1 and R2, higher wall MTR and higher wall K-trans than neurocysticercosis. | In a 2026 prospective study of 53 ring-enhancing lesions a pre-contrast core R2 cut-off of 15.90 s-1 separated the two with 100 percent sensitivity and specificity, tuberculomas falling above it; wall MTR at or above 0.22 gave 86 percent sensitivity and 88 percent specificity [6]. |
Tuberculoma vs glioma on MRI
The overlap that causes the most trouble is the giant tuberculoma, larger than 2 cm, against an IDH-wild-type grade 4 glioma. The most useful comparison comes from a series that evaluated 32 giant tuberculomas against 20 histologically and genetically proven grade 4 gliomas with multiparametric MRI [3].
| Feature | Tuberculoma | High-grade glioma |
|---|---|---|
| Core on T2 | Hypointense or lamellated and whorled; a compact hypointense core. Pronounced intralesional T2 hypointensity in 25 percent, whorled or lamellated appearance in 53 percent [3] | Hyperintense necrotic core |
| Submarginal rim | T2 hyperintense crescent beneath the periphery in 78 percent [3] | Absent |
| Core on T1 | Iso to hyperintense caseum; T1 hyperintense rim on MT images in 78 percent [3] | Hypointense |
| Enhancement | Smooth, thin, complete rim | Thick, irregular, nodular rim; significantly greater mean rim thickness [3] |
| Diffusion | Peripheral rim of restriction in 69 percent; DWI-ADC mismatch; higher normalised ADC from core and rim [3] | Restriction in the cellular solid components; lower normalised ADC |
| SWI | Complete regular hypointense peripheral ring in 58 to 63 percent [3][4] | Irregular, incomplete blooming from haemorrhage and neovascularity |
| MR spectroscopy | Prominent lipid resonance in 94 percent; Cho/Cr about 1.36 [3][4] | Cho/Cr about 2.63, high Cho/NAA; lipid and lactate present but not dominant [4] |
| Perfusion | Low core rCBV; curve overshoot above baseline in 90 percent [3] | Significantly higher rCBV [3] |
| Number and oedema | Often multiple; oedema disproportionate to a modest mass effect | Usually solitary, infiltrative, with mass effect proportional to size |
| Course on therapy | Shrinks or reorganises on anti-tubercular therapy over weeks to months, sometimes after transient enlargement | Progresses without oncological treatment |
One caution worth carrying into a report. Two of the most quoted discriminators are less reliable than they look: diffusion did not separate tuberculomas from gliomas or metastases at all in the largest prospective series [4], and a lipid peak by itself appears in necrotic high-grade tumours too. What holds up is the combination of a low choline with a large lipid peak, a clean complete susceptibility ring and a T2 hypointense or lamellated core. When those disagree with each other, biopsy is the right answer rather than an empirical trial.
Tuberculoma vs neurocysticercosis
In endemic countries this is the commoner and more consequential dilemma, because the treatments diverge completely and because a small ring-enhancing lesion in a patient with new-onset seizures is one of the most frequent studies in the department.
| Feature | Tuberculoma | Neurocysticercosis (colloidal or granular-nodular) |
|---|---|---|
| Size | Often larger than 20 mm | Usually 20 mm or smaller |
| Shape | Irregular, lobulated or conglomerate | Round and regular |
| Scolex | Absent | Eccentric mural nodule when visible, and its demonstration is an absolute diagnostic criterion [11] |
| T2 core | Hypointense or mixed | Hyperintense, following fluid |
| Core ADC | 0.61 to 1.24 depending on stage [1] | 1.51 (degenerating) to 1.66 (vesicular) [1] |
| T2 relaxation time | Mean 161 ms [8] | Mean 617 ms [8] |
| Spectroscopy | Lipid present in 86 percent [7] | Lipid present in 20 percent; very low metabolite levels with a poor signal-to-noise spectrum, itself a marker [7] |
| Wall rCBV | About 3.3; cut-off 1.965 gives 90 percent sensitivity, 100 percent specificity [5] | About 1.3 [5] |
| Wall MTR | At or above 0.22 in 86 percent [6] | Lower [6] |
| Oedema | Often extensive and disproportionate | Usually mild and proportionate |
| Course | Slow response over months of anti-tubercular therapy | Spontaneous resolution of a single enhancing lesion is a confirmative diagnostic criterion [11] |
Cysticercosis also has something tuberculoma lacks: a formal, validated diagnostic framework. The revised Del Brutto criteria classify findings as absolute (histology, a subretinal cyst, or a scolex demonstrated within a cyst), major neuroimaging (cystic lesions without a scolex, enhancing lesions, multilobulated cysts, calcifications), confirmative (resolution after cysticidal therapy, spontaneous resolution of a single enhancing lesion, a migrating ventricular cyst), or minor (hydrocephalus, leptomeningeal enhancement), and combine them with clinical and exposure criteria [11]. Working through that list is often faster than agonising over signal characteristics.
Tuberculoma vs abscess and the wider ring-enhancing differential
A pyogenic abscess restricts markedly, with a mean core ADC of about 0.87 (SD 0.05), and diffusion separates abscess from non-abscess cystic lesions with 96 percent sensitivity and 96 percent specificity [10]. That is a genuinely powerful test, with one important blind spot: a tuberculous abscess restricts just as hard, with a core ADC of about 0.61 [1]. Diffusion therefore tells you a lesion is an abscess, not what organism is in it. Spectroscopy is what fills the gap, since pyogenic pus produces amino acids, acetate and succinate that tuberculous caseum does not.
| Diagnosis | The feature that separates it |
|---|---|
| Pyogenic abscess | Marked core restriction (ADC about 0.87), a smooth thin rim thinner on its ventricular side, and amino acid, acetate and succinate peaks on spectroscopy [10] |
| Toxoplasmosis | Advanced HIV with a low CD4 count, basal ganglia and grey-white junction predilection, an eccentric target sign, and thallium-201 SPECT or FDG PET negativity that separates it from lymphoma |
| Primary CNS lymphoma | Homogeneous avid enhancement in the immunocompetent, marked restriction from hypercellularity, and periventricular subependymal spread; ring enhancement mainly in the immunosuppressed |
| Metastasis | Grey-white junction, multiple lesions with oedema out of proportion, and a known primary. Spectroscopy shows high choline in the enhancing rim, unlike tuberculoma |
| Subacute infarct | Vascular territory, gyriform enhancement, evolving diffusion signal that matches the clinical timeline |
| Tumefactive demyelination | Incomplete, open ring enhancement with the open edge towards the cortex, and less mass effect than the size suggests |
| Radiation necrosis | Prior radiation field, low rCBV and low choline, spreading wavefront or Swiss-cheese enhancement |
Other patterns of CNS tuberculosis to look for
A tuberculoma rarely appears alone in the imaging record. The 2026 international guideline recommends baseline neuroimaging in anyone being evaluated for tuberculous meningitis, both because consistent features raise the probability of the diagnosis and because mass lesions and raised intracranial pressure must be excluded before lumbar puncture [12]. Any of the following alongside a ring-enhancing lesion moves tuberculosis to the top of the list.
| Manifestation | Imaging findings | Why it matters |
|---|---|---|
| Tuberculous meningitis | Thick enhancing exudate filling the basal cisterns, especially the suprasellar and ambient cisterns; best seen on post-contrast FLAIR or MT T1 | The commonest and most lethal form; drives the whole management pathway |
| Hydrocephalus | Communicating hydrocephalus from exudate blocking CSF resorption, occasionally obstructive | Occurs in 50 to 90 percent of tuberculous meningitis and may need a shunt or endoscopic third ventriculostomy [12] |
| Vasculitic infarcts | Basal ganglia, internal capsule and thalamic infarcts in the territory of the lenticulostriate and thalamoperforating vessels; the tuberculous zone | Cerebral infarction occurs in more than 65 percent and predicts poor outcome [12] |
| Tuberculous abscess | Larger, thin-walled, solitary, markedly restricting | Progresses faster; may need drainage |
| Optochiasmatic arachnoiditis | Enhancing soft tissue encasing the optic chiasm and nerves | A sight-threatening inflammatory complication treated with steroids and sometimes thalidomide or anti-TNF agents [12] |
| Spinal involvement | Arachnoiditis with clumped nerve roots, cord tuberculomas, intramedullary or epidural collections | Add spinal imaging when there are cord or root signs |
How to report a suspected tuberculoma
- Describe the core signal explicitly. State whether the centre is T2 hypointense, mildly hyperintense or frankly hyperintense. This single sentence sets the stage and predicts the diffusion behaviour.
- Give the ADC number, not just the DWI impression. Sample the core and the wall separately and say which is lower. A core lower than the wall means liquefaction.
- Report the SWI ring as complete or incomplete. A complete, regular hypointense ring is a positive finding worth naming.
- Quote the spectroscopy ratios. Cho/Cr and the presence and height of the lipid and lactate resonance. A large lipid peak with a low choline is the tuberculoma signature.
- Count the lesions and look at the base of the brain. Post-contrast FLAIR or MT T1 through the basal cisterns costs a few minutes and finds the exudate that confirms the diagnosis.
- Check the basal ganglia and internal capsules for infarcts and comment on ventricular size, since both change management immediately.
- Give a differential with a next step. If the picture is mixed, say what would resolve it: a chest radiograph and sputum testing, CSF Xpert Ultra PCR and culture, or biopsy. The 2026 guideline gives Xpert and Xpert Ultra PCR strong recommendations for CSF diagnosis alongside mycobacterial culture [12].
Treatment, follow-up imaging and the paradoxical response
Radiologists are asked two things about tuberculomas after the diagnosis is made: how long the lesion should take to go, and what it means when it gets bigger.
| Guideline | Regimen and duration | Corticosteroids |
|---|---|---|
| NICE NG33 [14] | CNS tuberculosis: isoniazid with pyridoxine, rifampicin, pyrazinamide and ethambutol for 2 months, then isoniazid and rifampicin for a further 10 months. Total 12 months. Do not routinely extend beyond 12 months in people with HIV | Dexamethasone or prednisolone at an initially high dose, withdrawn gradually over 4 to 8 weeks |
| WHO consolidated guidelines module 4 [13] | Children and adolescents with tuberculous meningitis: 2HRZE then 10HR, total 12 months (strong recommendation). A 6-month intensive regimen, 6HRZEto, is a conditional alternative, and should not be used in children living with HIV | Dexamethasone or prednisolone tapered over 6 to 8 weeks, given regardless of meningitis severity (strong recommendation, moderate certainty) |
| Tuberculous meningitis clinical practice guideline 2026 [12] | Insufficient evidence to recommend shortening adult treatment below 12 months. Baseline neuroimaging is recommended | Strong recommendation for use in people without HIV (high certainty); weak recommendation in people living with HIV, decided case by case |
The paradoxical response
Existing tuberculomas enlarging, or new ones appearing, on effective anti-tubercular therapy is a recognised and reasonably common event, typically in the first three months. It reflects a recovering immune response to mycobacterial antigen, not drug failure. The 2026 guideline records inflammatory intracerebral complications in around 20 percent of patients with tuberculous meningitis and in more than 30 percent of people living with HIV, and states plainly that clinical deterioration after starting treatment is an unreliable indicator of multidrug-resistant disease, because hydrocephalus, infarcts and inflammatory complications explain it more often [12].
The imaging report should say so. Anti-tubercular therapy is continued, corticosteroids are added or escalated, and thalidomide or a TNF-blocking agent such as infliximab has been used in refractory intracerebral inflammation, though the guideline found the evidence insufficient to recommend any of them formally [12]. Surgery has no established timing: no study has compared operating on a tuberculoma at diagnosis against operating after medical treatment fails [12].
For the follow-up scan itself, useful markers of a genuine response on therapy are reduction of the peripheral T1 hyperintensity, compaction of the T2 hypointense core, expansion of the submarginal T2 hyperintense rim, and increasing peripheral susceptibility, which were seen in 62.5 percent of giant tuberculomas followed on treatment [3]. Lesions can take many months to resolve and calcified residua are common, so an unchanged small calcified focus at 12 months is not treatment failure.
Frequently asked questions
References
- Gupta RK, Prakash M, Mishra AM, Husain M, Prasad KN, Husain N. Role of diffusion weighted imaging in differentiation of intracranial tuberculoma and tuberculous abscess from cysticercus granulomas: a report of more than 100 lesions. Eur J Radiol. 2005;55(3):384-392. PMID 16129246.
- Peng J, Ouyang Y, Fang WD, Luo TY, Li YM, Lv FJ, et al. Differentiation of intracranial tuberculomas and high grade gliomas using proton MR spectroscopy and diffusion MR imaging. Eur J Radiol. 2012;81(12):4057-4063. PMID 22749802.
- Peer S, Tiwari S, Swaminathan AD, Jabeen S, Saini J, Prasad C, et al. Multiparametric magnetic resonance imaging features of giant intracranial tuberculomas. Clin Neurol Neurosurg. 2021;210:107006. PMID 34739879.
- Parry AH, Wani AH, Shaheen FA, Wani AA, Feroz I, Ilyas M. Evaluation of intracranial tuberculomas using diffusion-weighted imaging, magnetic resonance spectroscopy and susceptibility weighted imaging. Br J Radiol. 2018;91(1091):20180342. PMID 29987985.
- Ghosh RN, Vyas S, Singh P, Khandelwal N, Sankhyan N, Singhi P. Perfusion magnetic resonance imaging in differentiation of neurocysticercosis and tuberculoma. Neuroradiology. 2019;61(3):257-263. PMID 30377746.
- Ahmad S, Singh P, Vyas S, Modi M, Sethi A, Dash S. Role of advanced multimodality synthetic MRI and dynamic contrast-enhanced MRI derived parameters in differentiating neurocysticercosis and tuberculomas. Clin Neuroradiol. 2026;36(2):611-622. PMID 41612059.
- Jayasundar R, Singh VP, Raghunathan P, Jain K, Banerji AK. Inflammatory granulomas: evaluation with proton MRS. NMR Biomed. 1999;12(3):139-144. PMID 10414948.
- Jayakumar PN, Srikanth SG, Chandrashekar HS, Subbakrishna DK. T2 relaxometry of ring lesions of the brain. Clin Radiol. 2007;62(4):370-375. PMID 17331832.
- Pui MH, Ahmad MN. Magnetization transfer imaging diagnosis of intracranial tuberculomas. Neuroradiology. 2002;44(3):210-215. PMID 11942374.
- Reddy JS, Mishra AM, Behari S, Husain M, Gupta V, Rastogi M, et al. The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. Surg Neurol. 2006;66(3):246-250. PMID 16935625.
- Del Brutto OH, Nash TE, White AC Jr, Rajshekhar V, Wilkins PP, Singh G, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017;372:202-210. PMID 28017213.
- Donovan J, Cresswell FV, Tucker EW, Davis AG, Rohlwink UK, Huynh J, et al. A clinical practice guideline for tuberculous meningitis. Lancet Infect Dis. 2026;26(2):e96-e111. PMID 40840485.
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment and care. Geneva: World Health Organization. 2025.
- National Institute for Health and Care Excellence. Tuberculosis. NICE guideline NG33. London: NICE. updated 2016.
- World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization. 2025.
Improve Content And Help Your Colleagues!
Found an error in the post? Please let us know using our contact page and we will update it with due credits!
If you wish to contribute radiological images for this case (or any other article on the website), you can submit them here and you will be duly credited: Submit radiology case